–
We are proud to announce the publication of our latest work in the Journal for ImmunoTherapy of Cancer (JITC):
“Synthetic DNA vaccine platform elicits potent immunity where electroporated naked-mRNA is non-immunogenic”.
This study represents an important milestone for NeoMatrix and our collaboration with 4basebio, demonstrating the potential of synthetic hairpin DNA (hpDNA) as a next-generation platform for personalized cancer vaccines.
Our data show that synthetic hpDNA delivered by electroporation induces:
- Strong neoantigen-specific CD8+ and CD4+ T-cell responses
- Durable immune memory
- Anti-tumor and anti-metastatic activity
- Synergy with immune checkpoint inhibitors
Importantly, the work highlights how delivery context and innate immune activation are critical determinants of vaccine immunogenicity.
What makes this particularly exciting is the use of fully synthetic, cell-free DNA manufacturing technology — enabling a scalable, rapid and highly pure platform potentially suited for individualized cancer immunotherapy.
We believe synthetic DNA represents a cutting-edge enabling technology for the future of precision medicine.
The paper is available online at: https://jitc.bmj.com/content/14/5/e013812
For more info:
Dr Luigi Aurisicchio (CEO)
Questo indirizzo email è protetto dagli spambots. È necessario abilitare JavaScript per vederlo.
Dr Fabio Palombo (CSO)
Questo indirizzo email è protetto dagli spambots. È necessario abilitare JavaScript per vederlo.
Neomatrix
Neomatrix is a biotech company created by a group of scientists with solid experience in Pharma and Biotech. The group has more than 15 years of experience and proven expertise in drug discovery in Oncology and is recognized for the design and implementation of a number of innovative technologies, including that of DNA gene therapy. Neomatrix’ core assets is its experience in the prediction of neoantigens and with electroporation delivery system, a technology that can be used for a variety of clinically useful applications, from vaccine development to somatic gene therapy.
For more info, visit www.neomatrixbiotech.com
